KK Series — Career Development

NIH K23 Grants — Mentored Patient-Oriented Research Career Development Award

Reviewed by Dr. Meng ZhaoLast reviewed June 9, 2026Data refreshed June 9, 2026Editorial standards

Mentored training for clinicians doing patient-oriented research

Funding

Salary support + ~$30K research/year

Duration

3–5 years

Eligibility

Clinicians focused on patient-oriented research

Activity code

K23

What is the NIH K23 grant?

The K23 is the NIH career development award for clinicians doing patient-oriented research — clinical trials, observational studies, behavioral interventions, and other research that directly involves human subjects. Like K08, it provides 75% protected research time and a research allowance for 3–5 years.

Recent K23 awards from NIH RePORTER

Examples of funded K23 projects across the last two fiscal years. The matching-award count comes from the full result set; funding totals, averages, rankings, and examples use the first 500 records returned by NIH RePORTER. Figures reflect a snapshot last refreshed on June 9, 2026.

Matching awards (last 2 FYs)
1,931
Full matching record count on RePORTER
Sampled funding
$89.3M
Sum of award amounts in the sample
Average award
$179K
Mean award amount in the sample

Example K23 projects from the sample

  • Pathogen and patient determinants of Candida gut colonization in critically ill patients

    5K23AI185174-03
    Max Adelman · METHODIST HOSPITAL RESEARCH INSTITUTE, TX · $194,036 · awarded Jun 5, 2026 · NIH

    PROJECT SUMMARY/ABSTRACT This K23 proposal outlines a five-year research and training plan that will accelerate Dr. Max Adelman’s career as an independent physician-scientist with expertise in Candida colonization and infection in critically ill patients. Dr. Adelman is an infectious diseases and critical care clinician whose translational research focuses…

  • Personalizing Antimicrobial Use in Ventilator-Associated Pneumonia

    5K23AI177689-03
    Owen Albin · UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI · $194,400 · awarded Jun 3, 2026 · NIH

    Candidate’s Long-Term Career Goals: To become an independent clinical investigator that strengthens ICU antimicrobial stewardship and personalizes antibiotic use in nosocomial pneumonia. Clinical Problems to be Addressed with this project: Ventilator-associated pneumonia (VAP) is common, costly, and a leading cause of morbidity and mortality in hospitalized…

  • Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: A Pilot Randomized Controlled Trial

    5K23DA055695-05
    Justin Berk · RHODE ISLAND HOSPITAL, RI · $195,696 · awarded Jun 3, 2026 · NIH

    PROJECT SUMMARY This K23 application proposes novel research in opioid use disorder (OUD) treatment in a correctional healthcare setting and a robust training plan to support the successful transition of the Dr. Justin Berk, MD MPH MBA (PI) to independent clinician-scientist. His background in public health, health management, and clinical medicine creates…

  • Developing a predictive risk score for pre-diabetes in youth.

    5K23DK139457-02
    Monica Bianco · LURIE CHILDREN'S HOSPITAL OF CHICAGO, IL · $189,172 · awarded Jun 3, 2026 · NIH

    PROJECT SUMMARY The prevalence of impaired glucose tolerance (IGT) and youth onset type 2 diabetes (YT2D) is increasing. IGT in adolescence is an indicator of increased risk for YT2D. Compared to adults, YT2D is associated with high therapeutic failure rates, decreased response to insulin sensitizers, and rapid progression to diabetes-related complications…

  • Localization of cerebral epileptiform activity during stereo EEG monitoring

    1K23NS142570-01A1
    Benjamin Cox · UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL · $237,870 · awarded Jun 3, 2026 · NIH

    Approximately 1/3 of patients with epilepsy are drug-resistant and should be considered for surgery. Successful epilepsy surgery depends on accurate localization of the seizure onset zone (SOZ), often requiring invasive monitoring with stereoelectroencephalography (sEEG). However, sEEG has inherent spatial limitations, and in many cases, imprecise…

  • Epidemiological assessment of Strongyloides stercoralis in at-risk populations in Texas

    1K23AI199607-01
    Megan Duffey · BAYLOR COLLEGE OF MEDICINE, TX · $191,219 · awarded Jun 3, 2026 · NIH

    Strongyloidiasis (causative agent Strongyloides stercoralis) is a neglected tropical disease that is often asymptomatic but causes severe morbidity and mortality when the infection becomes disseminated in periods of host immunosuppression. Due to the auto-infective portion of the S. stercoralis lifecycle, infections can persist for decades, long after a…

  • Virtual Reality Suicidal Decision Exposure: An Experimental Therapeutics Approach to Targeting Suicide Capability Mechanisms

    1K23MH137687-01A1
    Sarah Brown · FLORIDA STATE UNIVERSITY, FL · $179,716 · awarded Jun 1, 2026 · NIH

    Project Summary/Abstract To curb the rising rates of suicide, interventions that directly target the causal mechanisms for suicidal behaviors (SB; i.e., suicide capability) are needed. Virtual reality (VR) suicidal decision scenarios are a valid and safe proxy for SB among at-risk individuals and have enabled causal examinations of suicide capability…

  • Combining Brain Stimulation with Computerized Cognitive Training for MCI

    5K23AG090691-02
    Stephanie Aghamoosa · MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC · $210,168 · awarded May 27, 2026 · NIH

    PROJECT SUMMARY/ABSTRACT The proposed K23 Award will support Dr. Stephanie Aghamoosa, PhD in launching an independent program of research developing non-pharmacological interventions for the secondary prevention of dementia. Dr. Aghamoosa is a clinical neuropsychologist whose long-term career goal is to become a federally-funded investigator conducting…

  • Examining the influence of sociodemographic and medical factors on plasma p-tau217 performance in at-risk populations

    5K23AG084850-03
    Corey Bolton · VANDERBILT UNIVERSITY MEDICAL CENTER, TN · $183,789 · awarded May 26, 2026 · NIH

    ABSTRACT. Alzheimer’s disease (AD) is a public health crisis that disproportionately affects individuals in the Black community. With recent advances in treatment, the need for early identification of AD pathology has never been greater. Early detection allows for early intervention which may be essential to slowing or stopping the progression of AD prior…

  • Longitudinal Academic Performance in Children with a History of Neonatal Abstinence Syndrome

    5K23DA055096-05
    Tammy Corr · PENNSYLVANIA STATE UNIV HERSHEY MED CTR, PA · $199,669 · awarded May 26, 2026 · NIH

    Project Summary/Abstract The objectives of this project are to more thoroughly understand the relationship between neonatal abstinence syndrome (NAS) and longitudinal academic performance. NAS is a withdrawal condition due to in utero drug exposure, most commonly opioids. The syndrome affects more than 32,000 newborns annually in the U.S., and its incidence…

  • Designing and piloting clinic-based health information technology to improve WIC retention

    5K23MD020103-02
    Kelsey Egan · BOSTON MEDICAL CENTER, MA · $166,738 · awarded May 26, 2026 · NIH

    PROJECT SUMMARY Food insecurity is a significant public health concern and a focus of federal policy and research due to its negative health impacts, including on the physical, behavioral, and developmental health of young children. Food insecurity remains prevalent in the US, with higher rates among Black and Hispanic households and households with…

  • Identifying individual clinical and environmental predictors of buprenorphine response to inform treatment for opioid use disorder

    1K23DA063863-01A1
    Allen Bailey · MCLEAN HOSPITAL, MA · $194,206 · awarded May 25, 2026 · NIH

    1 Project Summary/Abstract 2 3 Despite evidence that buprenorphine maintenance is an effective treatment for many individuals with opioid 4 use disorder (OUD), nearly half of patients receiving buprenorphine for OUD either return to illicit opioid use or 5 prematurely discontinue treatment. However, we do not know who is unlikely to respond to buprenorphine…

Funding institutes in the sample

InstituteAwardsFunding
NIH500$89.3M

Most frequent institutions in the sample

  1. UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 25 awards
  2. MASSACHUSETTS GENERAL HOSPITAL 24 awards
  3. UNIVERSITY OF PENNSYLVANIA 22 awards
  4. JOHNS HOPKINS UNIVERSITY 17 awards
  5. UNIVERSITY OF MICHIGAN AT ANN ARBOR 16 awards
  6. VANDERBILT UNIVERSITY MEDICAL CENTER 14 awards
  7. BRIGHAM AND WOMEN'S HOSPITAL 14 awards
  8. UNIVERSITY OF PITTSBURGH AT PITTSBURGH 13 awards

Source: NIH RePORTER. Verify any award in the official record by searching its project number. See our data methodology for how this sample is built and its limitations.

Decision guide

Choose K23 when

Choose K23 when your research directly involves human subjects: trials, registries, biobanks, behavioral interventions.

Choose another mechanism when

Choose K08 for primarily lab-based research even if you're a clinician.

Who applies for K23

Clinicians within ~5 years of training completion who plan a research career focused on patient-oriented investigation.

Compare nearby NIH grant mechanisms

Searchers often land on K23 while deciding between adjacent NIH activity codes. Compare scope, NIH staff involvement, budget scale, and applicant stage before choosing a funding opportunity.

For broad grant lookup, use the NIH grant search to find funded examples by activity code, PI, institution, and award year.

Search tips for K23

  • K23 awards are useful predictors of clinical trial PIs in early career.

Search NIH grants by activity code

Find K23-funded PIs

K23 funding trends

K23 frequently asked questions

What is the difference between K08 and K23?

K08 = lab research for clinicians. K23 = patient-oriented research for clinicians. Both are 3–5 year mentored awards with 75% effort.

Related NIH grant types